Pharmaceuticals, Biotechnology and Life Sciences
Medexprim has appointed Montaine Marteau as Chief Product and Technical Officer (CPTO), concurrently with her integration into the company’s Executive Committee, alongside Romain Cazavan, Nicolas Dubost and Fabrice Pillon.
CARSON CITY, Nev. & LONDON–(BUSINESS WIRE)–The Committee to Restore Nymox Shareholder Value, LLC (“CRNSV”), with a goal to recover shareholder…
The National Institute for Health and Care Excellence (NICE) announced Thursday that empagliflozin (Jardiance) is recommended for use as an option for treating symptomatic chronic heart failure with preserved or mildly reduced ejection fraction in adults.
AstraZeneca said Tuesday it has made agreements in the product liability litigations related to Nexium and Prilosec. The company said…
Moderna announced Wednesday positive results from a clinical trial of mRNA-1083, its combination mRNA combination flu/COVID vaccine.
Mainz Biomed, a molecular genetics diagnostic company specializing in the early detection of cancer, has launched its flagship product, ColoAlert — a highly effective and user-friendly at-home detection test for colorectal cancer (CRC) – with its partner Bioclinica, a leader in the Romanian healthcare sector.
Exscientia provided Tuesday an update on its pipeline prioritisation strategy designed to further strengthen the Company’s focus, investment and infrastructure on programmes of greatest potential for differentiation and value creation, outlinging strategy which will support continued investment into market-leading technology while maintaining cash runway well into 2026.
New cancer cases rose by 2.3 % compared to 2020, to reach 2.74 million in 2022. Similarly, cancer deaths went up by 2.4 % compared to 2020, according to the European Commission’s estimates published in the European Cancer Information System (ECIS).
Novartis announced Monday positive top-line results from the pre-specified interim analysis of the Phase III APPLAUSE-IgAN study (NCT04578834) at 9 months.
AIDS Healthcare Foundation (AHF) acknowledged today pharmaceutical company Johnson & Johnson’s (J&J) announcement that it will not enforce its patent for the multi-drug resistant tuberculosis treatment SIRTURO (bedaquiline) for 134 low- and middle-income countries—a significant step in ending the global TB crisis for a preventable, treatable, and curable disease.